VCYT (Veracyte) Short Ratio


VCYT Veracyte Inc VCYT
75 GF Score
Price $57.10
GF Value $38.18
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Veracyte Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

VCYT
75GF Score
Veracyte Inc VCYT
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Veracyte (VCYT) Overvalued in 2026?

Based on GuruFocus' analysis, Veracyte stock appears to be overvalued. The current stock price of $57.10 is trading 49.6% above its estimated GF Value™ of $38.18. GuruFocus considers Veracyte to be Significantly Overvalued.

Key valuation signals for VCYT:

  • Short Ratio:
  • GF Value™: $38.18 vs. price of $57.10 (49.6% above fair value)
  • GF Score™: 75/100 with 7 warning signs

No single metric tells the full story. See the VCYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Veracyte Business Description

Other Exchanges 12V:Germany
Address 6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
75GF Score

Get the complete analysis for VCYT

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$57.10
Price
$38.18
GF Value